T. Rowe Price Associates’s BeOne Medicines Ltd ONC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $556M | Buy |
|
|||||
|
2025
Q2 | $247M | Sell |
|
|||||
|
2025
Q1 | $739M | Sell |
|
|||||
|
2024
Q4 | $543M | Buy |
|
|||||
|
2024
Q3 | $606M | Buy |
|
|||||
|
2024
Q2 | $324M | Buy |
|
|||||
|
2024
Q1 | $317M | Buy |
|
|||||
|
2023
Q4 | $344M | Buy |
|
|||||
|
2023
Q3 | $315M | Buy |
|
|||||
|
2023
Q2 | $265M | Buy |
|
|||||
|
2023
Q1 | $167M | Buy |
|
|||||
|
2022
Q4 | $101M | Buy |
|
|||||
|
2022
Q3 | $60.3M | Sell |
|
|||||
|
2022
Q2 | $74.8M | Sell |
|
|||||
|
2022
Q1 | $99.3M | Sell |
|
|||||
|
2021
Q4 | $151M | Sell |
|
|||||
|
2021
Q3 | $207M | Sell |
|
|||||
|
2021
Q2 | $200M | Sell |
|
|||||
|
2021
Q1 | $254M | Sell |
|
|||||
|
2020
Q4 | $216M | Buy |
|
|||||
|
2020
Q3 | $225M | Buy |
|
|||||
|
2020
Q2 | $113M | Buy |
|
|||||
|
2020
Q1 | $64.2M | Sell |
|
|||||
|
2019
Q4 | $97.7M | Sell |
|
|||||
|
2019
Q3 | $80.2M | Sell |
|
|||||
|
2019
Q2 | $91.8M | Sell |
|
|||||
|
2019
Q1 | $106M | Sell |
|
|||||
|
2018
Q4 | $133M | Sell |
|
|||||
|
2018
Q3 | $221M | Sell |
|
|||||
|
2018
Q2 | $218M | Sell |
|
|||||
|
2018
Q1 | $239M | Buy |
|
|||||
|
2017
Q4 | $88M | Sell |
|
|||||
|
2017
Q3 | $100M | Buy |
|
|||||
|
2017
Q2 | $40.8M | Sell |
|
|||||
|
2017
Q1 | $37.9M | Sell |
|
|||||
|
2016
Q4 | $32.5M | Sell |
|
|||||
|
2016
Q3 | $34M | Buy |
|
|||||
|
2016
Q2 | $13.5M | Buy |
|
|||||
|
2016
Q1 | $13.3M | Buy |
|